IPS Therapeutique (IPST)

IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models. At IPST we believe each study is worthy of tailored protocols designed to maximize the scientific and strategic value of the data generated. We believe in taking ownership of the studies entrusted to IPST while ensuring mutual collaboration for developing and agreeing to overall project plans. Established in 1999, we have conducted more than 3,000 preclinical cardiac safety and efficacy studies and over 120 GLP-compliant studies in support of FDA, EMEA, Health Canada and MoHW. IPS Therapeutique (IPST) has a 24,000 square-foot state-of-the-art purpose-designed laboratory and office complex located in Sherbrooke, Quebec – in close proximity to Montréal, Québec, Burlington and Boston. At IPST, our senior management team is fully engaged on every project. We invite our clients to talk through challenges, business requirements and quantitative expectations for each project. Our team understands the linkages between tasks, projects costs and schedules Cardiac models: HFpEF, HFrEF, dilated cardiomyopathy, hypertensive hear failure, hypertrophic cardiomyopathy, pulmonary artery banding, transverse aortic constriction, myocardial infarction, infective endocarditis Vascular models: Sugen 5416 and hypoxia induced PAH, monocrotaline induced PAH, hypoxia induced acute PAH, hemorrhagic shock, preeclampsia Inflammatory and fibrotic disorders: CCl4 induced liver fibrosis, bile duct ligation, inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), silicosis, NASH and NAFLD, skin sclerosis Respiratory models: Acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), chronic cough, poly (I:C) induced lung inflammation Coagulation models: Venous stasis, FeCl3 induced arterial thrombosis, immune thrombocytopenia, anticoagulant reversal